<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933788</url>
  </required_header>
  <id_info>
    <org_study_id>ESCORT_DM</org_study_id>
    <nct_id>NCT02933788</nct_id>
  </id_info>
  <brief_title>Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients</brief_title>
  <official_title>Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the more suitable treatment for the prevention of vascular complications
      in diabetes patents who were at high cardiovascular risk group by comparing the platelet
      aggregation inhibitory effect of aspirin and cilostazol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is a dangerous disease with high risk of vascular complications. Thus, to prevent
      these vascular complication, antithrombotic drug may be administered. Representative
      antithrombotic agents are aspirin and cilostazol. However, recent studies suggested that
      aspirin did not have sufficient effect to prevent vascular complications of diabetes. For
      that reason, it have been reported that antithrombotic effects of aspirin were falling in
      diabetes patients, so-called 'aspirin resistance.

      On the other hand, cilostazol used as the control drug inhibits atherosclerosis in diabetes
      patients in the studies of Asia including Korea, and it is effective to inhibit the risk of
      various cardiovascular disease. Therefore, cilostazol is likely to use drugs as substitute
      for aspirin therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reactivity testing</measure>
    <time_frame>Change from Baseline 'platelet reactivity testing(Aspirin reaction units and platelet function testing-100) at 14 days</time_frame>
    <description>Blood sampling is collected at baseline and after taking each drugs 14 days, in the fasting state . The rate of Aspirin reaction units(ARU) change compared baseline is measured through Verify Now. The rate of platelet aggregation(seconds) dut to collagen, epinephrine was compared through the platelet function testing-100.
Verify Now(ARU): It is a test developed to monitor the platelet aggregation inhibitory effects of anti-platelet drugs which used to prevent thrombosis and relapse it. By measuring the light transmission change, it outputs result to the aspirin response units(ARU)
Platelet function testing-100: platelet function analyser The cartridge membrane is coated by collagen as initial matrix for platelet adhesion. When platelet adhere to the collagen, it takes place the first physical stimulation. Then, another membrane component, Adenosine diphosphate induces platelet aggregation. The analysis equipment is measuring CT(closing time) in seconds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observation of Clinical laboratory data(total cholesterol, HDL, LDL and triglyceride</measure>
    <time_frame>Change from baseline &quot;total cholesterol, HDL, LDL and triglyceride, hsCRP, cluster of designation antigen 40, ligand, Dipeptidyl peptidase-4 enzyme activity, total and active glucagon like peptide-1' at 14 days.</time_frame>
    <description>The rate of lipid profile(total cholesterol, HDL, LDL and triglyceride) change which is cardiovascular risk factors and diabetes mellitus complication indicators change are measured at baseline and after taking each drugs for 14 days. Thus, the effect of each drugs preventing complication in patients with diabetes mellitus may be analyzed.
- total cholesterol(mg/dL)/ HDL(mg/dL)/ LDL(mg/dL)/ triglyceride(mg/dL)/ hsCRP(mg/dL)/ cluster of designation antigen 40(mg/dL)/ Dipeptidyl peptidase-4 enzyme activity(uM/ml)/ total and active glucagon like peptide-1(pmol/l)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cilostazol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.</description>
    <arm_group_label>Cilostazol group</arm_group_label>
    <other_name>Pletal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.</description>
    <arm_group_label>Aspirin group</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Who have one more following risk factor:

               -  Family history of cardiovascular disease

               -  Hypertension

               -  Smoking History

               -  Dyslipidemia

               -  Albuminuria

          -  Who do not have high risk of bleeding

          -  Who stop taking Cilostazol or Aspirin before randomized period 1months or

          -  Who have never taken the drugs

        Exclusion Criteria:

          -  Type 1 diabetes mellitus, gestational diabetes

          -  Who with history of macrovascular complication including cardiovascular disease,
             cerebrovascular disease and peripheral vascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol Young Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanbuk Samsung Diabetes Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Hyun Kim, Fellow</last_name>
    <phone>+2-2001-8503</phone>
    <email>kjhys0527@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheol Young Park, Professor</last_name>
    <phone>+2-2001-1550</phone>
    <email>cydoctor@chol.com</email>
  </overall_contact_backup>
  <link>
    <url>http://www.who.int/nmh/publications/ncd_report_full_en.pdf</url>
    <description>updated 2015 Mar 16</description>
  </link>
  <reference>
    <citation>Global status report on noncommunicable diseases 2010</citation>
  </reference>
  <reference>
    <citation>Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9. Erratum in: Lancet. 2010 Sep 18;376(9745):958. Hillage, H L [corrected to Hillege, H L].</citation>
    <PMID>20609967</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015 Apr;33(2):97-111. doi: 10.2337/diaclin.33.2.97.</citation>
    <PMID>25897193</PMID>
  </reference>
  <reference>
    <citation>Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9. Erratum in: JAMA. 2009 May 13;301(18):1882. JAMA. 2012 Nov 14;308(18):1861.</citation>
    <PMID>18997198</PMID>
  </reference>
  <reference>
    <citation>Kim JD, Park CY, Ahn KJ, Cho JH, Choi KM, Kang JG, Kim JH, Lee KY, Lee BW, Mok JO, Moon MK, Park JY, Park SW. Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. Atherosclerosis. 2014 May;234(1):146-51. doi: 10.1016/j.atherosclerosis.2014.01.015. Epub 2014 Feb 12.</citation>
    <PMID>24657383</PMID>
  </reference>
  <reference>
    <citation>Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications. 2008 May-Jun;22(3):224-8. doi: 10.1016/j.jdiacomp.2007.05.002. Epub 2008 Apr 16.</citation>
    <PMID>18413227</PMID>
  </reference>
  <reference>
    <citation>Araki S, Matsuno H, Haneda M, Koya D, Kanno Y, Kume S, Isshiki K, Araki H, Ugi S, Kawai H, Kashiwagi A, Uzu T, Maegawa H. Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin. Diabetes Care. 2013 Jul;36(7):e92-3. doi: 10.2337/dc12-2702.</citation>
    <PMID>23801816</PMID>
  </reference>
  <reference>
    <citation>Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 Feb 5;391(6667):591-4.</citation>
    <PMID>9468137</PMID>
  </reference>
  <reference>
    <citation>Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990 Jun 21;322(25):1769-74.</citation>
    <PMID>2345567</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Ji Hyun Kim</investigator_full_name>
    <investigator_title>Fellowship</investigator_title>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

